NASDAQ:TTNP

Titan Pharmaceuticals Stock Forecast, Price & News

$2.47
-0.03 (-1.20 %)
(As of 06/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.42
$2.49
50-Day Range
$2.24
$2.70
52-Week Range
$2.15
$13.35
Volume69,934 shs
Average Volume979,039 shs
Market Capitalization$24.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.78
30 days | 90 days | 365 days | Advanced Chart
Receive TTNP News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Titan Pharmaceuticals logo

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

Headlines

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Update
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Update
June 16, 2021 |  americanbankingnews.com
How to Buy Penny Stocks
How to Buy Penny Stocks
June 10, 2021 |  benzinga.com
Maxim Group Upgrades Titan Pharma As ProNeura Pivots To Pruritus
Maxim Group Upgrades Titan Pharma As 'ProNeura Pivots To Pruritus'
February 18, 2021 |  markets.businessinsider.com
Stock Alert: Titan Pharmaceuticals Rises 18%
Stock Alert: Titan Pharmaceuticals Rises 18%
February 1, 2021 |  nasdaq.com
TTNP Jan 2021 7.500 put
TTNP Jan 2021 7.500 put
January 10, 2021 |  uk.finance.yahoo.com
TTNP Dec 2020 7.500 call
TTNP Dec 2020 7.500 call
December 19, 2020 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

945th out of 2,101 stocks

Biological Products, Except Diagnostic Industry

135th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions

Is Titan Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Titan Pharmaceuticals stock.
View analyst ratings for Titan Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Titan Pharmaceuticals?

Wall Street analysts have given Titan Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Titan Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Titan Pharmaceuticals?

Titan Pharmaceuticals saw a decline in short interest during the month of May. As of May 28th, there was short interest totaling 679,500 shares, a decline of 24.0% from the May 13th total of 894,200 shares. Based on an average trading volume of 327,800 shares, the short-interest ratio is currently 2.1 days. Currently, 6.9% of the shares of the stock are sold short.
View Titan Pharmaceuticals' Short Interest
.

When is Titan Pharmaceuticals' next earnings date?

Titan Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Titan Pharmaceuticals
.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings data on Monday, May, 17th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $0.68 million for the quarter. Titan Pharmaceuticals had a negative net margin of 348.18% and a negative trailing twelve-month return on equity of 189.49%.
View Titan Pharmaceuticals' earnings history
.

How has Titan Pharmaceuticals' stock price been impacted by Coronavirus?

Titan Pharmaceuticals' stock was trading at $7.3350 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TTNP shares have decreased by 66.3% and is now trading at $2.47.
View which stocks have been most impacted by COVID-19
.

When did Titan Pharmaceuticals' stock split? How did Titan Pharmaceuticals' stock split work?

Shares of Titan Pharmaceuticals reverse split on the morning of Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for TTNP?

1 brokers have issued twelve-month price objectives for Titan Pharmaceuticals' shares. Their forecasts range from $11.00 to $11.00. On average, they expect Titan Pharmaceuticals' stock price to reach $11.00 in the next year. This suggests a possible upside of 345.3% from the stock's current price.
View analysts' price targets for Titan Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Titan Pharmaceuticals' key executives?

Titan Pharmaceuticals' management team includes the following people:
  • Dr. Marc Rubin, Exec. Chairman & Principal Exec. Officer (Age 66, Pay $250.52k)
  • Dr. Katherine L. Beebe-DeVarney Ph.D., Pres, COO & Director (Age 59, Pay $365k)
  • Mr. Brian E. Crowley, VP of Fin.
  • Mr. Mike Fritz, National Sales Director
  • Jennifer Kiernan, Exec. Assistant to CEO & Investor Communications Coordinator
  • Joe Schrei, Exec. Director of Commercial Operations

Who are some of Titan Pharmaceuticals' key competitors?

What other stocks do shareholders of Titan Pharmaceuticals own?

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

Who are Titan Pharmaceuticals' major shareholders?

Titan Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include GSA Capital Partners LLP (0.40%), UBS Group AG (0.24%), Credit Suisse AG (0.24%), Bank of New York Mellon Corp (0.18%) and Millennium Management LLC (0.17%).
View institutional ownership trends for Titan Pharmaceuticals
.

Which institutional investors are buying Titan Pharmaceuticals stock?

TTNP stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Credit Suisse AG, Bank of New York Mellon Corp, UBS Group AG, and Millennium Management LLC.
View insider buying and selling activity for Titan Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $2.47.

How much money does Titan Pharmaceuticals make?

Titan Pharmaceuticals has a market capitalization of $24.36 million and generates $4.84 million in revenue each year.

How many employees does Titan Pharmaceuticals have?

Titan Pharmaceuticals employs 12 workers across the globe.

What is Titan Pharmaceuticals' official website?

The official website for Titan Pharmaceuticals is www.titanpharm.com.

Where are Titan Pharmaceuticals' headquarters?

Titan Pharmaceuticals is headquartered at 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.